Business Context and Reporting Period
Company: LeMaitre Vascular, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2007
Business Overview: LeMaitre Vascular is a global provider of medical devices and implants for the treatment of peripheral vascular disease. The company operates in a single segment, offering 14 product lines across three categories: Endovascular & Dialysis Access, Vascular, and General Surgery. The company pursues growth through a direct sales force, acquisitions, and in-house manufacturing. In 2007, the company completed three strategic acquisitions: Cardiovascular Innovations (LeverEdge Contrast Injector), Vascular Architects (EndoRE line), and Biomateriali S.r.l. (Albograft vascular grafts).
Key Financial Metrics
| Metric | 2007 (in thousands) | 2006 (in thousands) |
|---|---|---|
| Net Sales | $41,446 | $34,628 |
| Gross Profit | $30,707 | $25,261 |
| Gross Margin | 74.1% | 72.9% |
| Operating Loss | $(4,283) | $(679) |
| Net Loss | $(2,934) | $(1,172) |
| Cash and Cash Equivalents | $6,691 | $17,626 |
| Marketable Securities | $16,198 | $13,182 |
| Total Current Assets | $42,060 | $43,641 |
| Total Liabilities | $12,565 | $6,264 |
| Stockholders' Equity | $48,586 | $50,699 |
Debt and Liquidity: As of December 31, 2007, the company had a $10 million revolving line of credit with no borrowings outstanding. The company holds approximately $22.9 million in cash, cash equivalents, and marketable securities. The company reported an accumulated deficit of approximately $12.9 million.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 20% to $41.4 million, driven by a 44% increase in the Endovascular & Dialysis Access category, foreign currency fluctuations, and the impact of 2007 acquisitions.
- Expense Increases: Operating expenses rose significantly, with Sales and Marketing up 28% (due to sales force expansion from 47 to 57 representatives), General and Administrative up 34% (public company costs), and R&D up 39%.
- Restructuring Charges: Restructuring charges increased 305% to $1.0 million, primarily due to termination fees for two European distributors as the company transitioned to direct sales.
- Profitability: The operating loss widened from $0.7 million in 2006 to $4.3 million in 2007. The net loss increased 150% to $2.9 million.
- Acquisitions: The company spent $5.1 million on acquisitions in 2007, adding the LeverEdge, EndoRE, and Albograft product lines.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance: Management does not expect to achieve profitability in the near term and projects a net loss for 2008. The company anticipates continued substantial operating expenses related to sales force expansion, clinical studies, and acquisitions.
Material Risks and Contingencies:
- Internal Controls: Management identified a material weakness in internal control over financial reporting regarding the determination of certain accruals and the reconciliation/review process of the financial statement close process. Consequently, disclosure controls and procedures were deemed ineffective as of December 31, 2007.
- Regulatory Issues: In January 2008, the FDA issued a Form 483 notification regarding the company's UniFit Abdominal Stent Graft clinical trial, citing inadequate supervision of sites and record-keeping. The company has submitted a response but faces potential enforcement actions.
- Acquisition Disputes: Following the Biomateriali acquisition, a customer notified the company of a reduction in purchases, leading to a $0.1 million inventory write-down and a projected $0.4 million intangible impairment in Q1 2008. The company has filed an indemnity claim against the sellers for approximately $0.5 million regarding undisclosed customer relationship information.
- Workforce Reduction: In January 2008, the company initiated a reorganization plan, incurring $0.4 million in severance costs for approximately 32 employees (13% of the workforce).
Key Facts for Investor Verification
- Profitability Trajectory: Verify the company's ability to convert revenue growth into profitability given the widening operating losses and explicit guidance for continued losses in 2008.
- Internal Control Remediation: Monitor the progress of remediation efforts for the material weakness in financial reporting controls to ensure future financial statement reliability.
- Regulatory Approval Status: Track the status of the UniFit Abdominal Stent Graft pivotal trial (UNITE study) and the FDA's response to the Form 483 observations, as U.S. market access for this key product depends on PMA approval.
- Acquisition Integration: Assess the financial impact of the Biomateriali acquisition, specifically the resolution of the indemnity claim and the stability of the distribution agreement with Edwards Lifesciences AG.
- Cash Burn Rate: Evaluate the sufficiency of the $22.9 million cash position against the projected cash needs for operations, clinical trials, and future acquisitions.